Lencioni R - Search Results

1

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Llovet JM, et al. Among authors: lencioni r. J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. J Natl Cancer Inst. 2008. PMID: 18477802 Review.

2

Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography.

Lencioni R, Della Pina C, Bruix J, Majno P, Grazioli L, Morana G, Filippone A, Laghi A, Bartolozzi C. Lencioni R, et al. Dig Dis Sci. 2005 Mar;50(3):533-7. doi: 10.1007/s10620-005-2469-0. Dig Dis Sci. 2005. PMID: 15810637 Clinical Trial.

3

Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead?

Lencioni R, Llovet JM. Lencioni R, et al. J Hepatol. 2005 Sep;43(3):377-80. doi: 10.1016/j.jhep.2005.06.001. J Hepatol. 2005. PMID: 16005537 No abstract available.

4

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Lencioni R, Llovet JM. Lencioni R, et al. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. Semin Liver Dis. 2010. PMID: 20175033 Review.

5

Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma.

Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Gish RG, et al. Among authors: lencioni r. Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):173-85. doi: 10.1586/egh.11.105. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22375523 Review.

6

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J. Lencioni R, et al. J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22. J Hepatol. 2016. PMID: 26809111 Clinical Trial.

7

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM. Lencioni R, et al. J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26. J Hepatol. 2017. PMID: 28131794 Free article. Clinical Trial.

8

Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made".

Montal R, Lencioni R, Llovet JM. Montal R, et al. Among authors: lencioni r. J Hepatol. 2017 Jul;67(1):196-197. doi: 10.1016/j.jhep.2017.03.004. Epub 2017 Mar 16. J Hepatol. 2017. PMID: 28315709 No abstract available.

9

Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.

Tak WY, Lin SM, Wang Y, Zheng J, Vecchione A, Park SY, Chen MH, Wong S, Xu R, Peng CY, Chiou YY, Huang GT, Cai J, Abdullah BJJ, Lee JS, Lee JY, Choi JY, Gopez-Cervantes J, Sherman M, Finn RS, Omata M, O'Neal M, Makris L, Borys N, Poon R, Lencioni R. Tak WY, et al. Among authors: lencioni r. Clin Cancer Res. 2018 Jan 1;24(1):73-83. doi: 10.1158/1078-0432.CCR-16-2433. Epub 2017 Oct 10. Clin Cancer Res. 2018. PMID: 29018051 Clinical Trial.

10

mRECIST for HCC: Performance and novel refinements.

Llovet JM, Lencioni R. Llovet JM, et al. Among authors: lencioni r. J Hepatol. 2020 Feb;72(2):288-306. doi: 10.1016/j.jhep.2019.09.026. J Hepatol. 2020. PMID: 31954493 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

238 results

Search Page